Cognitive function · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Incidence of dementia · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding (intracranial and extracranial) · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Functional ability · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Stroke or transient ischaemic attack · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Any adverse events (excluding major bleeding) · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Withdrawal from study medication · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Death or dependence · acute ischaemic stroke
Antiplatelet drug probably leads to lower death or dependence at end of compared with control (moderate certainty).
1 finding from 1 review
Death from any cause during · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes death from any cause during compared with control (very low certainty).
1 finding from 1 review
Pulmonary embolism · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).
1 finding from 1 review
Recurrent ischaemic or unknown stroke during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes recurrent ischaemic/unknown stroke during treatment period compared with control (very low certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Major extracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes major extracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Complete recovery from stroke (post hoc) · acute ischaemic stroke
Antiplatelet drug probably leads to higher complete recovery from stroke (post hoc) compared with control (moderate certainty).
1 finding from 1 review